



The following resources and tools were referenced during the LTC+ Webinar on the Use of Antivirals in Long-Term Care

Antiviral Resource	Description	Link
Canadian Adaptive Platform Trial of Treatments for Covid in Community Settings (CanTreatCOVID) Study	Article/Study	Link
Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19	Article/Study	Link
Real-world effectiveness of nirmatrelvir/ritonavir use for COVID-19: A population-based cohort study in Ontario, Canada	Article/Study	Link
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB	Article/Study	Link
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19	Article/Study	Link
Therapeutic Brief: Crushing Nirmatrelvir/ritonavir (Paxlovid)	Article/Study	Link
Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial	Article/Study	Link
Canadian Adaptive Platform Trial of Treatments for Covid in Community Settings (CanTreatCOVID)	Study	Link
Paxlovid for Treatment of Long Covid (STOP-PASC)	Study	Link
Evidence Brief for Primacy Care: Ontario Health Recommendations on the use of Paxlovid: January 17th, 2023	Tool	Link
Evidence Brief for Primacy Care: Ontario Health Recommendations on the use of Paxlovid: January 13th, 2023	Tool	Link
Paxlovid: For a Patient on a DOAC who is also a high risk of hospitalization from COVID-19 (e.g., unvaccinated, immunocompromised, or over 60 years old)	Tool	Link
The Liverpool Drug Interaction Group: Interaction Checker	Tool	Link
Michigan Medicine: Management of Paxlovid Drug-Drug Interactions	Tool	Link
Nirmatrelvir/Ritonavir (Paxlovid): What Prescribers and Pharmacists Need to Know	Tool	Link

To view the LTC+ webinar recording, please visit our LTC+ Website: <https://lctplus.ca/primary-care-provider/#Education-and-Webinars>